| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1590-8658(08)60530-7 |
| P698 | PubMed publication ID | 18598993 |
| P2093 | author name string | S Danese | |
| P2860 | cites work | TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. | Q52568596 |
| Impaired On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich Elements | Q62819809 | ||
| INFLIXIMAB DOWNREGULATES INTERFERON-γ PRODUCTION IN ACTIVATED GUT T-LYMPHOCYTES FROM PATIENTS WITH CROHN'S DISEASE | Q63727345 | ||
| Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway | Q77061247 | ||
| Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies | Q80611351 | ||
| Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease | Q80837962 | ||
| TNF/TNFR family members in costimulation of T cell responses | Q28240053 | ||
| TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis | Q30310991 | ||
| Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab | Q33793922 | ||
| Etiopathogenesis of inflammatory bowel diseases | Q33866988 | ||
| Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease | Q34145454 | ||
| Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease | Q35596219 | ||
| The CD40/CD40L costimulatory pathway in inflammatory bowel disease | Q35596631 | ||
| Increased gut permeability in Crohn's disease: is TNF the link? | Q35948456 | ||
| Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. | Q36259898 | ||
| Alterations of mesenchymal and endothelial cells in inflammatory bowel diseases | Q36451319 | ||
| Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation | Q36809550 | ||
| Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow | Q36838888 | ||
| Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. | Q41941349 | ||
| Impact of infliximab on serum leptin levels in patients with Crohn's disease | Q46398438 | ||
| Inflammatory bowel disease: etiology and pathogenesis | Q47899867 | ||
| P921 | main subject | inflammation | Q101991 |
| inflammatory bowel diseases | Q917447 | ||
| P304 | page(s) | S225-8 | |
| P577 | publication date | 2008-07-01 | |
| P1433 | published in | Digestive and Liver Disease | Q15766194 |
| P1476 | title | Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker | |
| P478 | volume | 40 Suppl 2 |
| Q38788593 | A 53-year-old man with dyspnoea, respiratory failure, consistent with infliximab-induced acute interstitial pneumonitis after an accelerated induction dosing schedule |
| Q37816445 | Adalimumab in ulcerative colitis: hypes and hopes |
| Q60313563 | Anti-TNF-α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease |
| Q46495260 | Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease |
| Q92589685 | Capturing the Biologic Onset of Inflammatory Bowel Diseases: Impact on Translational and Clinical Science |
| Q26994776 | Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update |
| Q54318216 | Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis. |
| Q42632507 | Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab--a pilot study. |
| Q91631853 | Endothelial MT1-MMP targeting limits intussusceptive angiogenesis and colitis via TSP1/nitric oxide axis |
| Q51584924 | Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. |
| Q39426072 | Genetics and immunodysfunction underlying Behçet's disease and immunomodulant treatment approaches |
| Q37310621 | Immunomodulatory and anti-inflammatory effects of chondroitin sulphate |
| Q57265340 | Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway* |
| Q37586911 | Maintenance treatment with infliximab for the management of Crohn's disease in adults |
| Q42029056 | Malignant melanoma of the ileo-anal pouch anastomosis after restorative proctocolectomy for ulcerative colitis: report of a case |
| Q37547257 | Overview of biologic therapy for Crohn's disease |
| Q26776139 | Promising biological therapies for ulcerative colitis: A review of the literature |
| Q64911664 | Reproducing the human mucosal environment ex vivo: inflammatory bowel disease as a paradigm. |
| Q34167771 | Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data |
| Q38104578 | State-of-the-art medical prevention of postoperative recurrence of Crohn's disease |
| Q38191334 | Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy? |
| Q47368079 | Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. |
| Q58611213 | The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity |
| Q38881849 | The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases |
| Q45839795 | Therapeutic Targets for Emerging Biologic Therapies in IBD. |
| Q92875750 | Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process |
| Q39020790 | Tumor necrosis factor suppresses NR5A2 activity and intestinal glucocorticoid synthesis to sustain chronic colitis |
Search more.